Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s share price gapped up before the market opened on Wednesday . The stock had previously closed at $27.60, but opened at $28.75. Celldex Therapeutics shares last traded at $27.28, with a volume of 216,928 shares.
Analyst Ratings Changes
CLDX has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Thursday, January 2nd. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a "neutral" rating and a $45.00 price objective for the company. Wolfe Research downgraded shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Wells Fargo & Company raised shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. Finally, Citigroup started coverage on Celldex Therapeutics in a report on Monday, October 7th. They set a "buy" rating and a $70.00 target price for the company. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $62.25.
Check Out Our Latest Research Report on CLDX
Celldex Therapeutics Stock Down 3.9 %
The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -10.32 and a beta of 1.62. The company has a 50-day moving average price of $26.11 and a 200-day moving average price of $32.56.
Insiders Place Their Bets
In related news, CEO Anthony S. Marucci acquired 11,500 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was acquired at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.80% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Celldex Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLDX. Wellington Management Group LLP lifted its holdings in shares of Celldex Therapeutics by 14.5% in the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock valued at $314,190,000 after buying an additional 1,167,659 shares during the period. Bellevue Group AG lifted its stake in Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company's stock valued at $104,404,000 after purchasing an additional 100,000 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company's stock worth $71,725,000 after buying an additional 654,194 shares in the last quarter. Geode Capital Management LLC grew its position in Celldex Therapeutics by 0.4% in the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company's stock worth $52,372,000 after buying an additional 6,557 shares during the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company's stock valued at $50,995,000 after buying an additional 479,068 shares in the last quarter.
About Celldex Therapeutics
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Read More
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
